Long Term Follow-Up of Subjects Exposed to GSK3377794

Overview

About this study

The purpose of this long-term, followup study is to evaluate subjects who have, during the interventional study, received GSK3377794 generated by a process that utilizes lentiviral vectors. Subjects enrolled in the interventional studies who complete the interventional study or who withdraw from the interventional study will enter this LTFU study and will be followed for up to 15 years from the infusion of genetically modified T lymphocytes. Subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects who have received at least one dose of GSK3377794 in the interventional study.
  • Subjects who have either completed the interventional study or have withdrawn from it.
  • Male or female subjects.
  • Capable of giving signed informed consent prior to the study participation.

Exclusion Criteria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Steven Attia, D.O.

Open for enrollment

Contact information:

Janet Hash B.S.

Hash.Janet@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Steven Robinson, M.B.B.S.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available
.
CLS-20502723

Mayo Clinic Footer